Potent and selective Foxo1 inhibitor; orally bioavailable
AS 1842856 is a potent and selective Foxo1 inhibitor (IC50 values are 33 nM at Foxo1 and >1 μM at Foxo3a and Foxo4); decreases Foxo-mediated promoter activity by 70%, 20% and 3% at Foxo1, Foxo4 and Foxo3, respectively. Regulates gluconeogenesis both
in vitro
in vivo
. Attenuates fasting plasma glucose level in diabetic db/db mice. Also suppresses autophagy, adipocyte differentiation and soluble guanylyl cyclase expression. Also inhibits STAT3 signaling in NSCLC. Orally bioavailable.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-124801 |
| Réf. fabricant | 18756916 |
| Nom chimique ou matériau | 5-Amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
| CAS | 836620-48-5 |
| Quantité | 50 mg |
| Formule moléculaire | C<sub>18</sub>H<sub>22</sub>FN<sub>3</sub>O<sub>3</sub> |
| Pureté | 98% |
